Preparation of Polydopamine-Modified 3D Interconnected Macroporous Silica for Laccase Immobilization

Dali Cao,Wenjing Cheng,Kai Tao,Yunxiao Liang 한국고분자학회 2018 Macromolecular Research Vol.26 No.7

Millimeter-sized polydopamine (PDA) modified three-dimensional interconnected macroporous silica (PDA/3DIMS) with high porosity, large pore volume and pore diameter was prepared and used as the support to immobilize commercial laccase (Lac) from Denilite II S. The skeleton of 3DIMS is constructed by silica nanofilm, so the PDA/3DIMS is constructed by PDA/SiO2/PDA sandwich nano-film. The immobilization conditions, incubation time, pH and enzyme concentration were optimized, and the properties of the immobilized laccase were investigated. The enzyme activity of Lac-PDA/3DIMS (295.9 U/g) was higher than that of Lac-3DIMS (222.2 U/g). The stability and reusability of the two immobilized laccases were both improved comparing with the free laccase. Lac-PDA/3DIMS exhibited higher retained activity (73.6%) than Lac-3DIMS (31.8%) after reused for ten times. Lac-PDA/3DIMS retained more than 84.0% initial activity after storage for a month, however, the free laccase and Lac-3DIMS were 7.1% and 48.6%, separately. These advantages revealed that PDA thin layer plays an important role to improve the enzymatic activity of immobilized laccase, and the PDA/3DIMS material is a very promising support for enzyme immobilization.

Improved Adaptive Compensation of Variant Fighter With Multiple Faults via Extended Observer

Kaiyu Hu,Wenjing Sun,Zian Cheng 제어·로봇·시스템학회 2023 International Journal of Control, Automation, and Vol.21 No.7

This research is devoted to devising a fault-tolerant control system to resolve the challenge of multi-fault automatic repair in variable-structure flight conditions of fighters. In the classical fighter system, the increment of the state parameter is used to represent the variable structure parameter. To illustrate the broad applicability of the following technique, Rudder and Sensor Gain Loss and Bias Faults are constructed. The Extended Observer is designed to simultaneously gauge faults, states, and disturbances. Furthermore, the harmonic functions is designed to quickly adapt to fighter configuration changes, time-varying disturbances, and to estimate all failures. Similar harmonic functions also appear in the design of fault self-healing algorithms, i.e., adaptive fault-tolerant controllers with variable-structure harmonic functions, simultaneously repairing gain loss and bias faults of rudder and sensors. Verification of the method’s effectiveness is achieved through semi-physical simulations, while the Lyapunov function function demonstrates the system’s stability.

Life prediction and optimal design of flange structure of tire unloader

Jingxiu Ling,Wenjing Wang,Long Cheng,Qianting Wang,Hao Zhang 대한기계학회 2023 JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY Vol.37 No.12

In the production process of the giant tire, the tire unloader needs to clamp and flip the tire, and the tire has a large inertia force, easy to cause vibration and lead to the failure of bearing parts, etc., then the flange is needed to play a fixed role. therefore, the rationality of flange design for the use of safety and service life are very important. For this reason, this paper simulates the flange connected to the tire unloader to obtain its stress history data, at the same time through genetic algorithm structure optimization analysis was carried out on the flange, it is concluded that the influence of structure parameters on the life of flange, and flange for structure optimization, get the optimized flange fatigue life 71 % increase compared to the original plan. The weight is reduced by 0.9 %, and the mechanical properties of the optimized flange are better.

Iron metabolism protein transferrin receptor 1 involves in cervical cancer progression by affecting gene expression and alternative splicing in HeLa cells

Huang Nan,Wei Yaxun,Cheng Yi,Wang Xiaolong,Wang Qi,Chen Dong,Li Wenjing 한국유전학회 2022 Genes & Genomics Vol.44 No.6

Background: Transferrin receptor 1 (TfR1), encoded by TFRC, is a key regulator of iron homeostasis and plays important roles in many diseases, including cancers. Objective: To decipher the underlying molecular functions of TfR1 based on its influence on transcriptome profile in cancer cells. Methods: In this study, we first identified the expression pattern and prognostic influence of TFRC in cervical cancer patients from TCGA database. To explore the regulatory outcomes of TfR1 from the view of whole transcriptome profile, we generated TFRC knockdown (TFRC-KD) HeLa cells and negative control (NC) cells using short hairpin RNA (shRNA) method. Unbiased transcriptome sequencing (RNA-seq) experiment was used to analyze the global expression level and alternative splicing (AS) changes between TFRC-KD and NC cells. Results: We found TFRC was consistently elevated in cervical cancer samples and tightly associated with prognosis of patients. Differential expression analysis revealed that 629 differentially expressed genes (DEGs) were identified between TFRC-KD and NC. Functional enrichment analysis of these DEGs revealed that TFRC-KD extensively disturbed cell physiology related pathways, including immunity, cell metabolism and gene expression. Moreover, dysregulated AS profile also indicated that TfR1 has important roles in the AS regulation. Hundreds of TfR1-regulated AS genes were involved in DNA repair, cell death, transcription and viral reproduction pathways, which were tightly associated with cancer cell progression. Conclusions: In summary, we for the first time explored the molecular functions of TfR1 at transcriptional and post-transcriptional levels. These results demonstrate TfR1 participates in the progression of cervical cancer by affecting the expression and AS levels of genes in cancer associated pathways, which greatly extends our understanding of TfR1 functions besides iron homeostasis and provide novel options in cancer treatment by targeting TfR1.

Impact of Hepatoprotective Medications on the Safety and Efficacy of OBV/PTV/r plus DSV ± Ribavirin in HCV GT1b-infected Asian Patients

( Wan-long Chuang ),( Yan Luo ),( Jeong Heo ),( Gui-qing Wang ),( Ming-lung Yu ),( Yoon Jun Kim ),( Qing Xie ),( Cheng-yuan Peng ),( Mingxiang Zhang ),( Yan Huang ),( Wenjing Lu ),( Linda M. Fredrick 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1

Aims: Hepatoprotective medications (HPMs) are commonly used in patients with chronic liver disease, especially across Asia. The phase 3 ONYX-I and ONYX-II studies evaluated the safety and efficacy of the 3-DAA regimen of ombitasvir and paritaprevir/ritonavir (OBV/PTV/r) plus dasabuvir (DSV) ± ribavirin (RBV) in an exclusively HCV GT1b-infected Asian population. This post-hoc analysis evaluated the impact of HPM use in patients treated with OBV/PTV/r + DSV ± RBV in these studies. Methods: ONYX-I and ONYX-II enrolled patients in China, South Korea and Taiwan. SVR12, treatment-emergent adverse events (AEs), and alanine transaminase (ALT) normalization, as well as mean changes in ALT over time were assessed in patients using vs not using HPMs. HPM use defined as all medications administered during any treatment period. Results: Overall, 11% (36/325) of non-cirrhotic and 57% (59/104) of cirrhotic patients were receiving HPMs, with ursodeoxycholic acid being the most commonly used in both non-cirrhotic (5.2% [17/325]) and cirrhotic (14.4% [15/104]) patients. SVR12 rates were high (99.7- 100%) in both non-cirrhotic and cirrhotic patients irrespective of HPM use. The regimen was generally well tolerated, with low rates of SAEs and AEs leading to treatment discontinuation (Table). Of patients with ALT above normal at baseline (BL), 100% vs 95% of non-cirrhotic and 98% vs 89% of cirrhotic patients using or not using HPMs, respectively, had normal ALT values at end of treatment (EOT). Mean ALT levels during treatment declined rapidly and similarly with and without HPM use; mean changes from BL to EOT were -38.8 and -37.0 U/L, respectively, in non-cirrhotic and -54.2 and -66.6 U/L, respectively, in cirrhotic patients. Conclusions: OBV/PTV/r + DSV ± RBV achieved high SVR12 and was generally well tolerated regardless of HPM use. HPM use had no impact on the safety profile of OBV/PTV/r + DSV therapy in Asian HCV infected subjects.

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Non-Cirrhotic Asian Patients with Genotype 1b HCV Infection: ONYX-I SVR24 Results

( Lai Wei ),( Jinlin Hou ),( Yan Luo ),( Jeong Heo ),( Chi-jen Chu ),( Zhongping Duan ),( Mong Cho ),( Jun Cheng ),( Jun Li ),( Jidong Jia ),( Wenjing Lu ),( Linda M Fredrick ),( Tami Pilot-matias ),( 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1

Aims: HCV genotype 1b is the most common genotype in Asian patients. ONYX-I is a phase 3, randomised, double-blind, placebo-controlled study of the 3-DAA regimen of OBV/PTV/r and DSV in treatment- naive and treatment-experienced non-cirrhotic patients with HCV GT1b infection in China, South Korea and Taiwan. Methods: In this study, the safety/efficacy of OBV/PTV/r + DSV administered for 12 weeks were evaluated in non-cirrhotic Asian patients. Patients in Arm A received active study drug during a 12-week double-blind (DB) period, while patients in Arm B received placebo during the same period followed by an open-label (OL) period in which they received 12 weeks of active study drug. Efficacy was assessed by SVR12 and SVR24. Efficacy and safety were assessed in all patients who received at least one dose of active study drugs. Results: 650 HCV GT1b patients (54% female, 100% Asian, 44% treatment-experienced) were enrolled from China (n=410) South Korea (n=120) and Taiwan (n=120), and randomised 1:1 to Arms A and B. In Arm A, SVR12 and SVR24 rates were 99.5% (183/184) in treatment-naive patients and 100% (141/141) in treatment- experienced patients. Most treatment-emergent adverse events (TEAEs) in patients receiving the active drug were mild in severity. The most common (≥5%) TEAEs in Arm A were upper respiratory tract infection (10.5%), headache (6.2%) and dizziness (5.2%). Seven patients had serious AEs during active treatment (Arm A) and one patient in Arm A discontinued treatment. Conclusions: In non-cirrhotic Asian adults with HCV GT1b-infection, treated with OBV/PTV/r + DSV for 12 weeks, SVR24 rates equalled previously reported SVR12 rates from this study (99.5% of treatment- naive and 100% of treatment-experienced patients), and are consistent with other clinical trials with this drug combination. The treatment was generally well tolerated with mostly mild TEAEs reported.